The Agilent xCELLigence RTCA CardioECR System
15 Mar 2023In this application note, Agilent introduces the xCELLigence RTCA CardioECR system, a dual-mode instrument that includes directed electrical pacing of hiPSC-CMs as well as simultaneous monitoring of hiPSC-CM viability, contraction, and FP in real-time. The multiplexed evaluation of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) using the CardioECR system allows for a suitable assay platform to predict drug-induced proarrhythmia, contractile liability, and chronic toxicity of drugs under development.
Related products
Request Quote for All Products
xCELLigence RTCA CardioECR
Agilent TechnologiesThe xCELLigence RTCA CardioECR instrument combines high-frequency measurement of cell-induced electrical impedance with multi-electrode array technology to simultaneously assess cardiomyocyte contractility, viability, and electrophysiology. The simultaneous recording of impedance and field potential by the xCELLigence RTCA CardioECR instrument provides a view of cardiomyocyte health at an unprecedented level of detail, enabling a deeper understanding of the mechanisms underlying drug-induced cardiac liability. The CardioECR can also be used to functionally mature hiPSC cardiomyocytes with its electronic pacing function. Paced hiPSC cardiomyocytes provide a significantly improved cell model used in various applications including safety/tox assessment, drug discovery, and cardiac disease research. For Research Use Only. Not for use in diagnostic procedures.